Do Children Taking SGAs Get Metabolic Monitoring?
Careful monitoring of adverse effects of psychotropic drugs in general and second-generation antipsychotics in particular falls below recommended standards for children and adolescents.
A New Treatment for Parkinson Disease Psychosis
In a placebo-controlled study of patients with Parkinson disease and psychosis, the 5-HT-2A receptor inverse agonist pimavanserin improved psychotic symptoms and did not worsen motor signs.
Ramelteon (Rozerem) to Prevent Delirium?
Preliminary results from using the melatonin-receptor agonist ramelteon (Rozerem) in hospitalized patients to prevent delirium are encouraging.
Starting Dose of Eszopiclone Lowered to Avoid Next-Day Impairment; Study Examines Determinants of Antipsychotic Treatment Response
Anxiolytics, Hypnotics, and Mortality Risk
In a retrospective cohort study, a significant association was found between the use of anxiolytic and hypnotic drugs and an increased risk of death.
In the Media
|Mental health care: How to spot the warning signs of severe mental illness||January 24, 2013|
|Stressed out? Tips for taking control||January 14, 2013|
|Long Working Hours Linked to Depression||January 27, 2012|
|Working long hours doubles depression odds||January 26, 2012|
|Exercise may boost mood for some chronically ill||January 25, 2012|